Is autoimmunity the Achilles' heel of cancer immunotherapy? (Q38687375)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Is autoimmunity the Achilles' heel of cancer immunotherapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

corrigendum / erratum

Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?

0 references

author

Carl H. June

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

3

Jeffrey A Bluestone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Jeremy T Warshauer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

English

0 references

publication date

1 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

540-547

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations

19 March 2020

cites work

1 reference

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

21 January 2018

1 reference

Prediction and pathogenesis in type 1 diabetes.

21 January 2018

1 reference

Tumor-specific killer cells in paraneoplastic cerebellar degeneration

21 January 2018

1 reference

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

21 January 2018

1 reference

Autoimmunity associated with immunotherapy of cancer

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Mechanisms of tolerance.

1 reference

Control of central and peripheral tolerance by Aire

21 January 2018

1 reference

Aire-dependent thymic development of tumor-associated regulatory T cells

21 January 2018

1 reference

The enemy within: keeping self-reactive T cells at bay in the periphery

21 January 2018

1 reference

Regulatory T cells and Foxp3

21 January 2018

1 reference

Regulatory T cells: mechanisms of differentiation and function

21 January 2018

1 reference

AIRE expands: new roles in immune tolerance and beyond.

21 January 2018

1 reference

Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?

21 January 2018

1 reference

CCR4 and its ligands: from bench to bedside

21 January 2018

1 reference

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

Modulation of tryptophan catabolism by regulatory T cells.

21 January 2018

1 reference

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells

21 January 2018

1 reference

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

21 January 2018

1 reference

Toxicities of Immunotherapy for the Practitioner

21 January 2018

1 reference

Current concepts in the diagnosis and management of cytokine release syndrome

21 January 2018

1 reference

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

Releasing the Brakes on Cancer Immunotherapy.

21 January 2018

1 reference

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

21 January 2018

1 reference

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

21 January 2018

1 reference

Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade

21 January 2018

1 reference

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.

21 January 2018

1 reference

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

21 January 2018

1 reference

Epitope spreading in immune-mediated diseases: implications for immunotherapy

21 January 2018

1 reference

Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help

21 January 2018

1 reference

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases

21 January 2018

1 reference

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression

21 January 2018

1 reference

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients

21 January 2018

1 reference

Cross-presentation by dendritic cells

21 January 2018

1 reference

Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells

21 January 2018

1 reference

The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies

21 January 2018

1 reference

CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis.

21 January 2018

1 reference

The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.

21 January 2018

1 reference

Roles of the EZH2 histone methyltransferase in cancer epigenetics

21 January 2018

1 reference

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

21 January 2018

1 reference

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy

21 January 2018

1 reference

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

21 January 2018

1 reference

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes

21 January 2018

1 reference

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

21 January 2018

1 reference

Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction

21 January 2018

1 reference

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade

21 January 2018

1 reference

The epigenetic landscape of T cell exhaustion.

21 January 2018

1 reference

Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.

21 January 2018

1 reference

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

21 January 2018

1 reference

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

Combination cancer immunotherapies tailored to the tumour microenvironment

21 January 2018

1 reference

Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis

21 January 2018

1 reference

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

21 January 2018

1 reference

Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies

21 January 2018

1 reference

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy

21 January 2018

1 reference

Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice

21 January 2018

1 reference

21 January 2018

1 reference

Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation.

21 January 2018

1 reference

Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1.

21 January 2018

1 reference

Control of autoimmune diseases by the vitamin D endocrine system

21 January 2018

1 reference

Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus

21 January 2018

1 reference

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

21 January 2018

1 reference

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

21 January 2018

1 reference

The microbiota in adaptive immune homeostasis and disease

21 January 2018

1 reference

Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut.

21 January 2018

1 reference

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer

21 January 2018

1 reference

Epidemiology and estimated population burden of selected autoimmune diseases in the United States

21 January 2018

1 reference

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

21 January 2018

1 reference

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

21 January 2018

1 reference

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

21 January 2018

1 reference

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

21 January 2018

1 reference

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

21 January 2018

1 reference

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

21 January 2018

1 reference

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases

21 January 2018

1 reference

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

21 January 2018

1 reference

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

21 January 2018

1 reference

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

21 January 2018

1 reference

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

21 January 2018

1 reference

Graft-versus-host disease

21 January 2018

1 reference

7 January 2021

Immunosuppression in the tumor microenvironment: where are we standing?

1 reference

7 January 2021

Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta

1 reference

7 January 2021

Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin

1 reference

7 January 2021

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

1 reference

7 January 2021

Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery

1 reference

7 January 2021

Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer

1 reference

7 January 2021

Identifiers

DOI

10.1038/NM.4321

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28475571%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference